Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04200339 · ClinicalTrials.gov registry record
Adolescent SCreening To Help Eliminate Misuse
A clinical trial of Substance Use, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- 810
- Enrollment target
- 1
- Study location
NCT04200339: Completed study of Substance Use, sponsored by Boston Children's Hospital.
NCT04200339 is a study of Substance Use that has completed, run by Boston Children's Hospital. The registered enrollment target is 810 participants, below the 1,251-participant average among 88 other Substance Use trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04200339, a study of Substance Use, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- 810 participants
- Enrollment target
- 1
- Study location
Study Summary
The specific aim of this study is to evaluate the performance of three substance use screening instruments (S2BI, BSTAD, and TAPS Tool) against a criterion standard of Diagnostic Statistical Manual - 5 (DSM-5) substance use disorder (SUD) diagnoses in an adolescent population.
Primary Outcome
The focus of this study is to evaluate the performance of each tool (S2BI, BSTAD, and TAPS Tool) in identifying substance use and substance use disorders at previously identified cut points for alcohol, marijuana and tobacco/nicotine for each tool. The properties that will be evaluated include sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (LR+) and negative likelihood ratio (LR-)
Conditions Studied
Study Locations (1)
Massachusetts
- Boston Childrens Hopsital - Adolecents Substance Use and Addiction Program - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 810 participants |
| Start Date | 2020-07-21 |
| Est. Completion | 2022-02-25 |
What the finished NCT04200339 record still lists
NCT04200339 is an observational study that tracks outcomes without assigning an intervention. The registered 810 participants enrollment target is mid-sized for trials with a published cap, below the 1,251-participant average among 88 other Substance Use trials with a reported enrollment target (35% lower).
The record links to 1 condition, with Substance Use appearing as the primary indexed condition, and to 0 interventions.
NCT04200339 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04200339 about?
NCT04200339 is a clinical study titled "Adolescent SCreening To Help Eliminate Misuse". The specific aim of this study is to evaluate the performance of three substance use screening instruments (S2BI, BSTAD, and TAPS Tool) against a criterion standard of Diagnostic Statistical Manual - 5 (DSM-5) substance use disorder (SUD) diagnoses in an adolescent population.
What is the current status of trial NCT04200339?
This trial is currently completed. The enrollment target is 810 participants. The study started on 2020-07-21. Estimated completion is 2022-02-25.
What conditions does trial NCT04200339 study?
This clinical trial studies the following conditions: Substance Use.
Who is sponsoring clinical trial NCT04200339?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04200339 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Use
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04200339's enrollment target sits among peer trials
810 10th of 88 higher than 79 of 88 other Substance Use trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Native Spirit: Significant Aim 3: Intervention
RECRUITING · NA
-
Parent SMART (Substance Misuse in Adolescents in Residential Treatment)
RECRUITING · NA
-
Cultural Adaptation of Drug Treatment for DJJ Youth
RECRUITING · NA
-
Adaptation and Evaluation of Bright Horizons
RECRUITING · NA
-
Teen Health Choices & Wellness
RECRUITING · NA
-
Pre-exposure Prophylaxis (PrEP) Uptake and Adherence Intervention for Women with Trauma-related Conditions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05519085 · 810 participants · Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- NCT06529094 · 808 participants · NA
Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- NCT06065098 · 806 participants · NA
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI